Edwards Lifesciences names Theodora Mistras as CFO effective May 29
Edwards Lifesciences said on May 4, 2026 that Theodora Mistras, currently CFO of Viatris, will become corporate vice president and chief financial officer effective May 29, 2026, succeeding Scott Ullem, who has held the role since 2014. The Offer Letter sets a $925,000 base salary, a $2,013,000 sign-on bonus, and an $8,000,000 initial RSU grant, with a $4,500,000 target fiscal 2026 annual equity award, which shareholders can use to gauge the cost of the leadership change.
Key points
- Mistras, age 44, has been CFO of Viatris since March 1, 2024; previously a managing director at Citigroup and Goldman Sachs healthcare investment banking.
- Offer Letter dated May 2, 2026: $925,000 base salary and target annual bonus of not less than 100% of base salary, plus a $2,013,000 sign-on bonus.
- Initial RSU award with a grant date value of $8,000,000, vesting 43.75%, 50% and 6.25% on the first, second and third anniversaries of her start date.
- Scott Ullem announced his planned transition in October; the press release says he will continue as a strategic advisor in the months ahead.
The filing
Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 1:42 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 04, 2026.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.